PROF
Profound Medical Corp. Common Stock
stockNASDAQ
an inside out approach to prostate ablation profound medical is a canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients. profound's novel technology combines real-time mr imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. it provides a highly precise treatment tailored to patient-specific anatomy and pathology. this method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. the potential of this technology is currently being demonstrated in clinical trials. for more information, visit profoundmedical.com
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 5.85 | 2026-10-01 | +15.64% | 8.487 |
| 1M | 6.81 | 2026-09-08 | -0.66% | 2.834 |
| 3M | 7.55 | 2026-07-08 | -10.40% | 1.334 |
| 6M | 6.49 | 2026-04-08 | +4.24% | 1.263 |
| 1Y | 6.74 | 2025-10-08 | +0.37% | 1.837 |
| 2Y | 7.70 | 2024-10-08 | -12.14% | — |
| 5Y | 14.24 | 2021-10-08 | -52.49% | 1.017 |
Profound Medical Corp. Common Stock (NASDAQ:PROF) stock price today is $6.77, and today's volume is 1,943,596. PROF is up 19.102% today. The 30 day average volume is 133,887. PROF market cap is $247.20M with 36.54M shares outstanding.